Try our mobile app

Switch to company model in classical logic    *

General information

Country: IRELAND

Sector: Biotechnology

Amarin Corporation PLC operates as a biopharmaceutical company. The Company commercializes and develops therapeutics to improve cardiovascular helath. Amarin serves patients worldwide.
Website: amarincorp.com



Growth: Bad revenue growth rate -16.7%, there is acceleration compared to average historical growth rates -19.2%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -20.5%

Profitability: LTM EBITDA margin is negative, -23.1%. On average the margin is decreasing steadily. Gross margin is high, +59.4%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 3.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 30.2% higher than minimum and 85.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -0.8x by EV / Sales multiple

Key Financials (Download financials)

Ticker: AMRN
Share price, USD:  (-1.4%)0.8593
year average price 1.0324  


year start price 1.3500 2023-04-22

max close price 1.4300 2023-07-18

min close price 0.6600 2023-11-02

current price 0.8593 2024-04-20
Common stocks: 407 655 000

Dividend Yield:  0.0%
Last revenue growth (y/y):  -16.7%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  -19.2%
Historical growth of EBITDA:  ---
EV / Sales: 0.1x
Margin (EBITDA LTM / Revenue): -23.1%
Fundamental value created in LTM:
Market Cap ($m): 350
Net Debt ($m): -312
EV (Enterprise Value): 38
Price to Book: 0.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-04Zacks Investment Research

Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe

2024-04-03The Motley Fool

Why Amarin Stock Was Rocketing Higher on Wednesday

2024-03-01Zacks Investment Research

Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates

2024-02-29Seeking Alpha

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript

2024-02-15Zacks Investment Research

5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates

2024-01-15Seeking Alpha

Amarin: Sarissa Is Giving Me Hope Again

2024-01-12Zacks Investment Research

Are Medical Stocks Lagging Amarin (AMRN) This Year?

2024-01-11Zacks Investment Research

Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results

2024-01-10The Motley Fool

Why Amarin Stock Skyrocketed Today

2024-01-10Seeking Alpha

Amarin Corporation plc (AMRN) CEO Pat Holt presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AMRN AMRN AMRN AMRN AMRN AMRN
reportedCurrency USD USD USD USD USD USD
cik 897 448 897 448 897 448 897 448 897 448 897 448
fillingDate 2024-02-29 2023-11-01 2023-08-02 2023-05-03 2023-03-01 2022-10-27
acceptedDate 2024-02-29 07:06:26 2023-11-01 07:05:30 2023-08-02 07:06:43 2023-05-03 07:05:36 2023-03-01 07:16:40 2022-10-27 07:07:13
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 75M 66M 80M 86M 90M 90M
costOfRevenue 31M 36M 37M 38M 27M 27M
grossProfit 45M 30M 43M 48M 64M 63M
grossProfitRatio 0.594 0.451 0.532 0.557 0.705 0.699
researchAndDevelopmentExpenses 5M 5M 6M 6M 5M 6M
generalAndAdministrativeExpenses 21M 21M 19M 27M 30M 26M
sellingAndMarketingExpenses 23M 24M 32M 32M 38M 32M
sellingGeneralAndAdministrativeExpenses 44M 45M 51M 60M 68M 59M
otherExpenses -1M -575 000 3M 624 000 1M 0
operatingExpenses 49M 51M 57M 65M 73M 65M
costAndExpenses 80M 87M 94M 103M 100M 92M
interestIncome 3M 3M 3M 2M 2M 750 000
interestExpense -1M 0 0 1M 1000.000 750 000
depreciationAndAmortization 740 385 734 000 732 000 765 000 3M 774 000
ebitda -4M -19M -3M -17M -7M 3M
ebitdaratio -0.052 -0.292 -0.039 -0.193 -0.077 0.029
operatingIncome -5M -21M -24M -17M -10M 2M
operatingIncomeRatio -0.062 -0.325 -0.299 -0.202 -0.108 0.020
totalOtherIncomeExpensesNet 2M -1M -7M 3M 3M -6M
incomeBeforeTax -2M -19M -18M -14M -7M -4M
incomeBeforeTaxRatio -0.033 -0.285 -0.223 -0.169 -0.075 -0.043
incomeTaxExpense 3M 501 000 -355 000 2M -8M 1M
netIncome -6M -19M -18M -16M 856 000 -5M
netIncomeRatio -0.077 -0.292 -0.219 -0.191 0.009 -0.057
eps -0.014 -0.047 -0.043 -0.041 0.002 -0.013
epsdiluted -0.014 -0.047 -0.043 -0.041 0.002 -0.013
weightedAverageShsOut 408M 408M 408M 406M 399M 405M
weightedAverageShsOutDil 408M 408M 408M 406M 402M 405M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AMRN AMRN AMRN AMRN AMRN AMRN
reportedCurrency USD USD USD USD USD USD
cik 897 448 897 448 897 448 897 448 897 448 897 448
fillingDate 2024-02-29 2023-11-01 2023-08-02 2023-05-03 2023-03-01 2022-10-27
acceptedDate 2024-02-29 07:06:26 2023-11-01 07:05:30 2023-08-02 07:06:43 2023-05-03 07:05:36 2023-03-01 07:16:40 2022-10-27 07:07:13
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 200M 271M 233M 191M 218M 240M
shortTermInvestments 121M 50M 80M 113M 92M 63M
cashAndShortTermInvestments 321M 321M 313M 304M 309M 304M
netReceivables 134M 122M 123M 133M 131M 123M
inventory 259M 254M 227M 226M 229M 228M
otherCurrentAssets 12M 19M 43M 20M 19M 28M
totalCurrentAssets 725M 718M 706M 684M 689M 687M
propertyPlantEquipmentNet 8M 9M 9M 9M 10M 9M
goodwill 0 0 0 0 0 0
intangibleAssets 19M 20M 20M 21M 22M 22M
goodwillAndIntangibleAssets 19M 20M 20M 21M 22M 22M
longTermInvestments 0 0 67 000 544 000 1M 2M
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 79M 93M 124M 145M 164M 188M
totalNonCurrentAssets 107M 122M 154M 176M 197M 222M
otherAssets 0 0 0 0 0 0
totalAssets 832M 839M 860M 860M 886M 908M
accountPayables 53M 53M 54M 59M 65M 93M
shortTermDebt 0 0 0 0 0 0
taxPayables 0 0 0 0 0 0
deferredRevenue 2M 2M 2M 2M 2M 2M
otherCurrentLiabilities 204M 211M 215M 183M 193M 192M
totalCurrentLiabilities 259M 267M 271M 244M 259M 287M
longTermDebt 9M 9M 9M 10M 10M 10M
deferredRevenueNonCurrent 3M 3M 3M 13M 13M 13M
deferredTaxLiabilitiesNonCurrent -1.000 0 0 0 0 0
otherNonCurrentLiabilities 9M 7M 7M 9M 8M -62M
totalNonCurrentLiabilities 20M 19M 20M 31M 31M 33M
otherLiabilities 1.000 0 0 0 0 0
capitalLeaseObligations 9M 9M 9M 10M 10M 10M
totalLiabilities 280M 286M 291M 275M 291M 320M
preferredStock 0 0 0 0 0 0
commonStock 303M 302M 302M 301M 299M 299M
retainedEarnings -1 586M -1 581M -1 561M -1 544M -1 527M -1 528M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0
othertotalStockholdersEquity 1 836M 1 831M 1 828M 1 827M 1 824M 1 817M
totalStockholdersEquity 552M 553M 569M 585M 595M 588M
totalEquity 552M 553M 569M 585M 595M 588M
totalLiabilitiesAndStockholdersEquity 832M 839M 860M 860M 886M 908M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 832M 839M 860M 860M 886M 908M
totalInvestments 121M 50M 80M 114M 93M 65M
totalDebt 9M 9M 9M 10M 10M 10M
netDebt -191M -262M -224M -182M -208M -231M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AMRN AMRN AMRN AMRN AMRN AMRN
reportedCurrency USD USD USD USD USD USD
cik 897 448 897 448 897 448 897 448 897 448 897 448
fillingDate 2024-02-29 2023-11-01 2023-08-02 2023-05-03 2023-03-01 2022-10-27
acceptedDate 2024-02-29 07:06:26 2023-11-01 07:05:30 2023-08-02 07:06:43 2023-05-03 07:05:36 2023-03-01 07:16:40 2022-10-27 07:07:13
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -6M -19M -18M -16M 856 000 -5M
depreciationAndAmortization 740 385 734 000 732 000 765 000 761 000 774 000
deferredIncomeTax -14M 262 000 13M 0 0 0
stockBasedCompensation 5M 4M 2M 6M 7M 5M
changeInWorkingCapital 844 244 23M 23M 4M -6M -19M
accountsReceivables -11M 330 000 11M -2M -8M 21M
inventory 10M 3M 20M 23M 23M 20M
accountsPayables -8M -4M 27M -15M -28M -66M
otherWorkingCapital 10M 24M -34M -1M 6M 6M
otherNonCashItems 13M -992 000 -14M -907 000 -284 000 182 000
netCashProvidedByOperatingActivities -651 564 7M 7M -7M 2M -18M
investmentsInPropertyPlantAndEquipment -510 959 -1000.000 -23 000 0 0 0
acquisitionsNet 31M -31M 23 000 0 0 0
purchasesOfInvestments -100M -33M -30M -53M -44M -23M
salesMaturitiesOfInvestments 29M 64M 64M 33M 17M 54M
otherInvestingActivites -31M 31M -23 000 0 -599 000 0
netCashUsedForInvestingActivites -71M 31M 34M -20M -28M 31M
debtRepayment 0 0 0 0 0 0
commonStockIssued 91 211 -2041.461 243 428 2M 60 000 0
commonStockRepurchased 2M -279 000 -187 000 0 605 000 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites -2M 4041.461 3572.000 -2M -627 000 -156 000
netCashUsedProvidedByFinancingActivities 83 242 -277 000 60 000 364 000 38 000 -156 000
effectOfForexChangesOnCash 94M -37M -57M 0 0 0
netChangeInCash -72M 38M 42M -26M -26M 12M
cashAtEndOfPeriod 200M 271M 234M 192M 218M 244M
cashAtBeginningOfPeriod 271M 234M 192M 218M 244M 232M
operatingCashFlow -651 564 7M 7M -7M 2M -18M
capitalExpenditure -510 959 -1000.000 -23 000 0 0 0
freeCashFlow -1M 7M 7M -7M 2M -18M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-29 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-03-01 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-29 12:00 ET
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-02-15 13:00 ET
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
2024-01-22 12:30 ET
Amarin Chairman & CEO Issue Letter to Shareholders
2024-01-10 12:00 ET
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
2023-12-11 13:00 ET
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-04 21:23 ET
Sarissa Capital Believes Amarin Stock Is Meaningfully Undervalued and Has Increased Its Ownership
2023-11-12 14:00 ET
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
2023-11-01 11:00 ET
Amarin Reports Third Quarter 2023 Financial Results
2023-10-31 16:00 ET
Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
2023-10-26 12:00 ET
Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023
2023-10-19 12:00 ET
 Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
2023-09-12 12:00 ET
Amarin to Present at the 2023 Cantor Global Healthcare Conference
2023-08-09 20:05 ET
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
2023-08-08 11:00 ET
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
2023-08-07 11:00 ET
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
2023-08-02 11:11 ET
Amarin Reports Second Quarter 2023 Financial Results
2023-08-02 11:11 ET
Amarin Reports Second Quarter 2023 Financial Results
2023-07-31 12:00 ET
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
2023-07-31 12:00 ET
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
2023-07-26 12:00 ET
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
2023-07-26 12:00 ET
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
2023-07-25 20:05 ET
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain
2023-07-25 20:05 ET
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain
2023-07-20 12:00 ET
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt
2023-07-20 12:00 ET
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt
2023-07-18 20:16 ET
Amarin Appoints Patrick Holt as President and Chief Executive Officer
2023-07-18 20:16 ET
Amarin Appoints Patrick Holt as President and Chief Executive Officer
2023-07-18 20:15 ET
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally
2023-07-18 20:15 ET
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally
2023-06-21 13:00 ET
Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)
2023-06-21 13:00 ET
Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)
2023-06-01 20:30 ET
Amarin to Present at Two Upcoming Investor Conferences
2023-06-01 10:00 ET
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
2023-06-01 10:00 ET
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
2023-05-12 15:00 ET
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
2023-05-12 15:00 ET
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
2023-05-03 11:00 ET
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
2023-05-03 11:00 ET
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
2023-04-19 12:00 ET
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
2023-04-19 12:00 ET
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
2023-04-17 11:00 ET
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
2023-04-17 11:00 ET
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
2023-04-04 12:00 ET
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
2023-04-04 12:00 ET
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
2023-03-16 12:00 ET
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
2023-03-16 12:00 ET
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
2023-03-06 21:05 ET
Amarin Announces Board Departures
2023-03-06 13:00 ET
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
2023-03-06 13:00 ET
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
2023-03-05 15:21 ET
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
2023-03-05 15:21 ET
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
2023-03-01 12:00 ET
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
2023-03-01 12:00 ET
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
2023-02-28 15:39 ET
Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide
2023-02-28 15:38 ET
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
2023-02-28 13:00 ET
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
2023-02-28 13:00 ET
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
2023-02-27 21:29 ET
Amarin Sets the Record Straight on Sarissa’s Latest Misstatements
2023-02-27 13:00 ET
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC
2023-02-27 13:00 ET
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC
2023-02-27 12:15 ET
Sarissa Capital Condemns Amarin Board for Frontrunning Results of Proxy Contest With Egregious Equity Grants to Executives
2023-02-22 13:00 ET
Amarin to Present at Cowen's 43rd Annual Health Care Conference
2023-02-22 13:00 ET
Amarin to Present at Cowen's 43rd Annual Health Care Conference
2023-02-21 13:30 ET
Sarissa Capital Reminds Amarin Shareholders Today Is the Last Day to Vote “FOR” Change
2023-02-21 13:00 ET
Amarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023
2023-02-21 13:00 ET
Amarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023
2023-02-20 18:00 ET
Sarissa Capital Urges Amarin Shareholders to Vote “FOR” Necessary Change
2023-02-17 14:03 ET
Amarin Urges Shareholders to Vote “Against” Sarissa’s Harmful Proposals at Upcoming General Meeting – IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE
2023-02-17 12:30 ET
Sarissa Capital Urges Amarin Shareholders to Vote for Change and Remake Amarin for Shareholders
2023-02-16 21:05 ET
Sarissa Capital Blasts Amarin’s Repeated False Statements; Clearly Amarin Will Say Anything to Keep Sarissa Off the Board
2023-02-16 17:34 ET
Leading Independent Proxy Firm ISS Joins Glass Lewis in Recommending that Amarin Shareholders Vote “AGAINST” Sarissa’s Value-Destructive Proposals
2023-02-16 14:44 ET
Amarin Clearly and Definitively Instructed Registrar to Accept ALL Submitted Proxy Cards
2023-02-15 21:29 ET
Sarissa Capital Uncovers That Amarin’s Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So
2023-02-14 22:09 ET
Sarissa Capital Disappointed That Amarin Webcast Continues Board’s Defense of Poor Results and Lack of Accountability
2023-02-14 00:47 ET
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Amarin Shareholders Vote “AGAINST” All of Sarissa’s Proposals
2023-02-13 13:00 ET
Amarin Shareholders Invited to Webcast with Board and Management Team
2023-02-13 13:00 ET
Sarissa Capital Warns of Amarin’s Expensive Attempts to Switch Votes by Inundating Shareholders With White Proxy Cards
2023-02-09 22:27 ET
Sarissa Capital Does Not Believe Amarin Cares About Shareholders
2023-02-09 13:00 ET
Amarin Mails Letter Highlighting Why Shareholders Should Vote on the WHITE Proxy Card “AGAINST” Sarissa’s Harmful Proposals
2023-02-07 21:35 ET
Sarissa Capital Highlights Amarin’s Inaccurate and Misleading Statements
2023-02-06 13:00 ET
Amarin Mails Letter to Shareholders Highlighting Sarissa’s Myths vs. The Facts
2023-02-03 22:16 ET
Sarissa Capital Highlights Amarin’s Disregard for Shareholder Interests and Urges Shareholders to Vote the BLUE Proxy Card for Change at Amarin
2023-02-02 21:30 ET
Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership
2023-02-01 21:09 ET
Sarissa Capital Urges Amarin Shareholders to Vote the Blue Card by February 22 to Fix Amarin for the Benefit of Shareholders
2023-01-31 13:24 ET
Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders
2023-01-31 13:24 ET
Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders
2023-01-27 13:45 ET
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand
2023-01-27 13:00 ET
Amarin to Present at SVB Securities Global Biopharma Conference
2023-01-27 13:00 ET
Amarin to Present at SVB Securities Global Biopharma Conference
2023-01-19 12:00 ET
Amarin Responds to Inaccurate and Misleading Statement by Sarissa
2023-01-19 12:00 ET
Amarin Responds to Inaccurate and Misleading Statement by Sarissa
2023-01-18 12:30 ET
Sarissa Capital Calls Out Amarin’s Sham Board Refreshment
2023-01-11 21:33 ET
Amarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders
2023-01-11 21:33 ET
Amarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders
2023-01-10 18:34 ET
Sarissa Capital Submits Notice to Call a Special Meeting of Amarin Shareholders to Add Directors and Remove Chairman Per Wold-Olsen
2023-01-10 12:15 ET
Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023
2023-01-10 12:15 ET
Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023
2023-01-10 12:00 ET
Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP
2023-01-10 12:00 ET
Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP
2022-12-14 12:00 ET
Amarin to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-14 12:00 ET
Amarin to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-07 13:30 ET
Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
2022-12-07 13:30 ET
Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
2022-11-15 12:00 ET
Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia
2022-11-15 12:00 ET
Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia
2022-11-09 13:00 ET
Amarin to Present at Jefferies London Healthcare Conference
2022-11-09 13:00 ET
Amarin to Present at Jefferies London Healthcare Conference
2022-11-07 13:00 ET
Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA®/VAZKEPA (icosapent ethyl) and Patient Care
2022-11-07 13:00 ET
Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA®/VAZKEPA (icosapent ethyl) and Patient Care
2022-10-27 11:00 ET
Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update
2022-10-27 11:00 ET
Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update
2022-10-20 20:30 ET
Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors
2022-10-20 20:30 ET
Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors
2022-10-20 12:00 ET
Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022
2022-10-20 12:00 ET
Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022
2022-10-11 20:15 ET
Amarin Board of Directors Issues Statement in Response to Sarissa
2022-10-11 20:15 ET
Amarin Board of Directors Issues Statement in Response to Sarissa
2022-10-11 11:30 ET
Sarissa Capital Has Commenced the Process to Call a Special Meeting of Amarin Shareholders to Remove and Replace Certain Board Members
2022-08-30 12:00 ET
Amarin to Present at H.C. Wainwright’s 24th Annual Global Investment Conference
2022-08-30 12:00 ET
Amarin to Present at H.C. Wainwright’s 24th Annual Global Investment Conference
2022-08-28 09:51 ET
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers
2022-08-28 09:51 ET
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers
2022-08-26 12:19 ET
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes
2022-08-26 12:19 ET
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes
2022-08-15 12:00 ET
Latest Research Evaluating VASCEPA®/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT® Landmark Outcomes Trial to be Presented at the European Society of Cardiology (ESC) Congress
2022-08-15 12:00 ET
Latest Research Evaluating VASCEPA®/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT® Landmark Outcomes Trial to be Presented at the European Society of Cardiology (ESC) Congress
2022-08-03 11:00 ET
Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update
2022-08-03 11:00 ET
Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update
2022-07-20 12:00 ET
Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022
2022-07-20 12:00 ET
Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022
2022-07-13 12:00 ET
NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & Wales
2022-07-13 12:00 ET
NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & Wales
2022-06-30 20:05 ET
REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo
2022-06-30 20:05 ET
REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo
2022-06-15 20:50 ET
Sarissa Capital Intends to Vote “Abstain” at the Amarin Annual Meeting
2022-06-10 10:00 ET
Amarin Receives Positive Recommendation from United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA® (icosapent ethyl)
2022-06-10 10:00 ET
Amarin Receives Positive Recommendation from United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA® (icosapent ethyl)
2022-06-06 12:30 ET
Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business
2022-06-06 12:15 ET
Amarin Appoints Tom Reilly as New Chief Financial Officer
2022-05-19 12:23 ET
Amarin Announces Appointment of New Directors and Board Leadership Changes
2022-05-19 12:23 ET
Amarin Announces Appointment of New Directors and Board Leadership Changes
2022-05-16 12:00 ET
Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs
2022-05-16 12:00 ET
Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs
2022-05-12 12:00 ET
Amarin to Present at Two Upcoming Investor Conferences
2022-05-12 12:00 ET
Amarin to Present at Two Upcoming Investor Conferences
2022-05-04 11:00 ET
Amarin Reports First Quarter 2022 Financial Results and Provides Business Update
2022-05-03 12:00 ET
New Analysis Reveals Icosapent Ethyl Significantly Reduces Risk of Major Cardiovascular Events in Patients with Prior Myocardial Infarction (Heart Attack)
2022-04-26 12:49 ET
Amarin Partner HLS Therapeutics Completes Reimbursement Negotiations with Pan-Canadian Pharmaceutical Alliance (pCPA) for VASCEPA® (icosapent ethyl)
2022-04-26 12:49 ET
Amarin Partner HLS Therapeutics Completes Reimbursement Negotiations with Pan-Canadian Pharmaceutical Alliance (pCPA) for VASCEPA® (icosapent ethyl)
2022-04-19 11:30 ET
Amarin to Report First Quarter 2022 Financial Results and Host Conference Call On May 4, 2022
2022-04-19 11:30 ET
Amarin to Report First Quarter 2022 Financial Results and Host Conference Call On May 4, 2022
2022-04-01 11:00 ET
Eicosapentaenoic Acid (EPA) Combined with Widely Used Statins Significantly Reduced Lipid Oxidation in Model Membranes
2022-03-28 11:00 ET
Amarin Receives Reimbursement for VAZKEPA® in Sweden
2022-03-28 11:00 ET
Amarin Receives Reimbursement for VAZKEPA® in Sweden
2022-03-21 12:30 ET
Latest Research Evaluating VASCEPA® (Icosapent Ethyl) to be Presented at the American College of Cardiology’s 71st Annual Scientific Session
2022-03-10 13:47 ET
Latest analysis shows VASCEPA® (icosapent ethyl) significantly lowered the risk of potentially fatal cardiovascular events in patients with prior percutaneous coronary intervention
2022-03-10 13:47 ET
Latest analysis shows VASCEPA® (icosapent ethyl) significantly lowered the risk of potentially fatal cardiovascular events in patients with prior percutaneous coronary intervention
2022-03-01 11:00 ET
Amarin Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
2022-02-25 13:00 ET
Amarin to Participate in Cowen 42nd Annual Health Care Conference
2022-02-24 12:30 ET
JAMA Publication Highlights VASCEPA® (Icosapent Ethyl) Cardiovascular Risk Reduction Extends to Cost Effectiveness at Patient Level
2022-02-15 13:00 ET
Amarin to Report Fourth Quarter and Full Year 2021 Financial Results And Host Conference Call on March 1, 2022
2022-01-10 12:00 ET
Amarin Provides Preliminary 2021 Revenue and Outlook for 2022
2022-01-04 12:00 ET
Amarin to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-11-16 12:00 ET
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at the American Heart Association Scientific Sessions 2021
2021-11-15 21:30 ET
Amarin Reports Subgroup Data from REDUCE-IT® Highlighting Benefits of VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Prior Peripheral Artery Disease (PAD) Presented in Rapid Fire Oral Session Presentation at the American Heart Association Scienti...
2021-11-11 12:00 ET
Amarin to Present at Two Upcoming Investor Conferences
2021-11-03 10:00 ET
Amarin Reports Third Quarter 2021 Financial Results and Provides Business Update
2021-10-20 11:05 ET
Amarin to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
2021-09-22 13:15 ET
Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S.
2021-09-13 11:00 ET
Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany
2021-09-13 10:00 ET
Amarin to Participate in September Investment Conferences
2021-08-31 11:00 ET
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at ESC Congress 2021, Organized by the European Society of Cardiology
2021-08-23 07:15 ET
Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Societ...
2021-08-16 11:00 ET
Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021, Organized by the European Society of Cardiology
2021-08-05 10:00 ET
Amarin Reports Second Quarter and Six Month 2021 Financial Results and Provides Business Update
2021-07-15 10:35 ET
Amarin to Report Second Quarter and Six Month 2021 Financial Results and Host Conference Call on August 5, 2021
2021-06-02 20:30 ET
Further Insights into Mechanism of Action of Icosapent Ethyl and Its Unique Form of Eicosapentaenoic Acid (EPA) Presented at the European Atherosclerosis Society (EAS) Congress 2021
2021-05-18 10:05 ET
Amarin to Present at Two Investor Conferences in June 2021
2021-05-17 20:05 ET
Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient at the American College of Cardiology’s 70th Annual Scientific Session
2021-05-15 12:00 ET
REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Potential Benefit in New Heart Failure in Studied At-Risk Patients as Presented at the American College of Cardiology’s 70th An...
2021-05-04 11:00 ET
Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology’s 70th Annual Scientific Session
2021-04-29 10:10 ET
Amarin Reports First Quarter 2021 Financial Results and Provides Business Update
2021-04-29 10:00 ET
Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel
2021-04-22 14:53 ET
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2
2021-04-20 10:05 ET
Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021
2021-04-17 13:50 ET
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021
2021-04-12 20:30 ET
Amarin Announces CEO Succession Plan
2021-04-06 10:05 ET
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication
2021-03-30 10:24 ET
Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk
2021-03-29 11:00 ET
Fifteen Medical Societies Now Recommend Icosapent Ethyl to Reduce Cardiovascular Risk, Further Supporting that VASCEPA® is Rapidly Becoming a New Standard of Care
2021-03-17 15:30 ET
VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Conference 2021
2021-02-25 10:55 ET
Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
2021-02-18 11:05 ET
Amarin to Present at Two Upcoming Investor Conferences
2021-02-17 13:05 ET
Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021
2021-02-09 12:00 ET
Amarin Provides Update on VASCEPA® (Icosapent Ethyl) Regulatory Review Processes in Mainland China and Hong Kong
2021-01-29 17:51 ET
Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction
2021-01-26 00:35 ET
Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit to Include Health Care Insurance Provider
2021-01-21 21:30 ET
Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases
2021-01-07 11:05 ET
Amarin Provides Preliminary 2020 Results and 2021 Outlook
2021-01-04 11:05 ET
Amarin to Present at 39th Annual J.P. Morgan Healthcare Conference
2020-12-14 10:00 ET
Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results
2020-12-13 02:30 ET
Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020
2020-12-07 12:00 ET
VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessions 2020
2020-12-01 00:55 ET
Amarin Files Patent Infringement Lawsuit Against Hikma
2020-11-24 11:05 ET
Amarin to Present at Piper Sandler’s 32nd Annual Healthcare Conference (Virtual)
2020-11-19 23:30 ET
Amarin Shares Topline Data from Partner’s Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China
2020-11-18 12:00 ET
Multiple New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at American Heart Association’s Virtual Scientific Sessions 2020
2020-11-11 21:30 ET
Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences
2020-11-05 11:00 ET
Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update
2020-10-29 11:00 ET
New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at American Heart Association’s Virtual Scientific Sessions 2020
2020-10-23 11:00 ET
U.S. Veterans with Decreased Renal Function Shown to Be at Higher Risk for Adverse Cardiovascular Events if They Have Moderately Elevated Triglyceride (TG) Levels Despite Well-Controlled Low-Density Lipoprotein (LDL)-Cholesterol
2020-10-19 11:00 ET
Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020
2020-10-05 11:00 ET
Latest Research Evaluating VASCEPA® (Icosapent Ethyl) Mechanisms of Action Presented at European Atherosclerosis Society (EAS) Congress 2020
2020-09-09 11:00 ET
Amarin to Present at the 2020 Cantor Virtual Global Healthcare Conference
2020-09-03 14:51 ET
Amarin Provides Update Following Ruling in VASCEPA® ANDA Patent Litigation
2020-09-01 20:30 ET
Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Risk Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology
2020-08-29 07:13 ET
VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020
2020-08-17 11:00 ET
Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology
2020-08-17 11:00 ET
Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology
2020-08-07 16:12 ET
Amarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent ethyl) in Reducing Viral Upper Respiratory Infections, Including COVID-19 and Flu, and the Clinical Severity of Such Infections
2020-08-04 14:38 ET
Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe
2020-08-04 10:30 ET
Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe
2020-08-04 10:00 ET
Amarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations
2020-07-27 11:00 ET
VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented as Encore at The American Society for Preventive Cardiology 2020 Virtual Summit on CVD (Cardiovascular Disease) Prevention
2020-07-21 20:15 ET
Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020
2020-06-16 20:30 ET
Amarin Announces Patent Litigation Settlement Agreement with Apotex Inc.
2020-06-15 11:00 ET
VASCEPA® (icosapent ethyl) Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study
2020-06-01 11:00 ET
Amarin Plans to Increase VASCEPA® (icosapent ethyl) Promotion and Education
2020-05-21 20:05 ET
Amarin Supports Trial to Investigate the Effects of VASCEPA® (icosapent ethyl) in the Treatment of COVID-19
2020-05-14 18:50 ET
VASCEPA® (icosapent ethyl) Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardiac Bypass Surgery, in Prespecified and Post Hoc Analyses of Landmark REDUCE-IT® Study
2020-04-30 09:00 ET
Amarin Reports First Quarter 2020 Financial Results and Provides Update on Operations
2020-04-28 11:00 ET
Amarin to Report First Quarter 2020 Results and Host Conference Call on April 30, 2020
2020-04-08 20:05 ET
Amarin to Host Conference Call on April 13, 2020 to Provide Preliminary First Quarter 2020 Results and Operational Update
2020-03-31 11:00 ET
Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC)
2020-03-30 22:25 ET
Amarin Comments on Ruling in VASCEPA® ANDA Litigation
2020-03-30 15:45 ET
Eicosapentaenoic Acid (EPA) Levels From VASCEPA® (Icosapent Ethyl) in REDUCE-IT® Strongly Correlated with Cardiovascular Outcomes
2020-03-15 17:56 ET
Amarin Takes Proactive Steps to Support Public Health Priorities
2020-02-25 21:05 ET
Amarin Reports Record Fourth Quarter and Full Year 2019 Financial Results and Provides Update on Operations
2020-02-20 11:00 ET
Amarin to Present at Two Upcoming Investor Conferences
2020-02-19 21:15 ET
Amarin To Report Fourth Quarter and Full Year 2019 Results and Host Conference Call on February 25, 2020
2020-02-07 02:26 ET
Amarin Honored by BioNJ with Innovator Award for VASCEPA® Development and Regulatory Approval
2020-01-13 11:00 ET
Amarin Launches True To Your Heart, a Campaign to Educate People on Persistent Cardiovascular Risk
2020-01-07 11:00 ET
Amarin Provides Update to Preliminary 2019 Results and Further Details on 2020 Outlook
2020-01-06 11:00 ET
Amarin to Present at 38th Annual J.P. Morgan Healthcare Conference
2020-01-02 11:00 ET
VASCEPA® Approved in Canada to Reduce the Risk of Cardiovascular Events
2019-12-13 23:14 ET
Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk
2019-12-13 21:48 ET
Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk
2019-12-02 11:00 ET
European Medicines Agency Accepts for Review Marketing Authorization Application for Amarin’s Icosapent Ethyl (Vascepa®) for Reduction of Cardiovascular Risk in High-Risk Patients, as Reflected in REDUCE-IT® Study
2019-11-18 22:30 ET
Amarin Highlights Key REDUCE-IT®-Related Data Presented at American Heart Association 2019 Scientific Sessions
2019-11-18 17:15 ET
Amarin’s John Thero Awarded EY Entrepreneur of The Year® 2019 Life Sciences National Award
2019-11-14 22:34 ET
Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsules Label Expansion to Reduce Cardiovascular Risk Based on Landmark REDUCE-IT® Outcomes Trial
2019-11-11 18:19 ET
New Analysis Shows Icosapent Ethyl (Vascepa®) Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthcare Costs When Used to Treat High-Risk Patients with Cardiovascular Disease or Diabetes and Other Risk Factors
2019-11-11 11:30 ET
REDUCE-IT® USA Results, in Prespecified Subgroup Analyses of Landmark REDUCE-IT Global Study, Showed Robust Cardiovascular Risk Reductions Across a Variety of Study Endpoints, Including Cardiovascular Death and All-Cause Mortality
2019-11-11 10:00 ET
Amarin to Present at the Jefferies 2019 London Healthcare Conference
2019-11-05 10:00 ET
Amarin Reports Third Quarter 2019 Financial Results and Provides Update on Operations
2019-11-04 11:00 ET
Seven Data Presentations Relevant to Vascepa® (Icosapent Ethyl) Capsules and Persistent Cardiovascular Risk to be Presented at American Heart Association’s 2019 Scientific Sessions, November 16 – 18
2019-10-24 20:30 ET
Amarin to Report Third Quarter 2019 Results and Host Conference Call on November 5, 2019
2019-10-17 13:48 ET
Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Patients at High Risk of Cardiovascular Events, such as Heart Attack, Stroke and Cardiac Death
2019-09-23 20:15 ET
Amarin to Participate in the Cantor Global Healthcare Conference
2019-09-16 10:00 ET
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on Statins
2019-08-09 12:53 ET
Amarin (AMRN) Alert: Johnson Fistel Launches Investigation into Amarin Corporation plc; Investors Encouraged to Contact Firm
2019-07-03 13:31 ET
Thinking about trading options or stock in Apple, Amarin, BP, Cisco Systems, or Morgan Stanley?
2019-04-10 00:51 ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation plc of Class Action Lawsuit and Upcoming Deadline - AMRN
2019-03-22 10:00 ET
AMARIN ALERT: Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact the Firm About Their Rights
2019-03-19 10:00 ET
Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology’s 68th Annual Scientific Session
2019-03-18 20:15 ET
Additional Real-World Data Show a Significant Risk Increase in Cardiovascular Events in People with Elevated Triglyceride Levels
2019-03-16 21:30 ET
High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Atherosclerotic Cardiovascular Disease
2019-03-05 11:00 ET
Amarin to Present at Cowen’s 39th Annual Health Care Conference
2019-03-04 21:30 ET
Important New Data on Vascepa® (Icosapent Ethyl) from the REDUCE-IT™ Trial to Be Presented Regarding Reduction in Total Ischemic Events
2019-03-01 22:00 ET
AMARIN INVESTOR ALERT: Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact the Firm About Their Rights

SEC forms

Show financial reports only

SEC form 10
2024-02-29 07:06 ET
Amarin reported for 2023 q4
SEC form 8
2024-02-29 07:05 ET
Amarin published news for 2023 q4
SEC form 8
2024-02-29 07:05 ET
Amarin published news for 2023 q4
SEC form 10
2024-02-29 00:00 ET
Amarin published news for 2023 q4
SEC form 8
2024-01-10 00:00 ET
Amarin published news for 2023 q4
SEC form 8
2024-01-10 00:00 ET
Amarin published news for 2023 q4
SEC form 8
2024-01-10 00:00 ET
Amarin published news for 2023 q4
SEC form 8
2023-11-01 07:05 ET
Amarin published news for 2023 q3
SEC form 10
2023-11-01 07:05 ET
Amarin reported for 2023 q3
SEC form 10
2023-11-01 00:00 ET
Amarin published news for 2023 q3
SEC form 10
2023-08-02 07:06 ET
Amarin reported for 2023 q2
SEC form 6
2023-08-02 07:01 ET
Amarin published news for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Amarin published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
Amarin published news for 2023 q2
SEC form 6
2023-07-28 18:46 ET
Amarin published news for 2023 q2
SEC form 6
2023-07-24 21:24 ET
Amarin published news for 2023 q2
SEC form 6
2023-07-20 08:31 ET
Amarin published news for 2023 q2
SEC form 6
2023-07-18 16:25 ET
Amarin published news for 2023 q2
SEC form 8
2023-07-18 00:00 ET
Amarin published news for 2023 q2
SEC form 6
2023-06-23 17:25 ET
Amarin published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
Amarin published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Amarin published news for 2023 q1
SEC form 8
2023-03-01 00:00 ET
Amarin reported for 2022 q4
SEC form 10
2023-03-01 00:00 ET
Amarin reported for 2022 q4
SEC form 8
2023-01-10 00:00 ET
Amarin published news for 2022 q4
SEC form 10
2022-10-27 00:00 ET
Amarin reported for 2022 q3
SEC form 8
2022-10-27 00:00 ET
Amarin reported for 2022 q3
SEC form 10
2022-08-03 00:00 ET
Amarin reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Amarin reported for 2022 q2
SEC form 10
2022-05-04 00:00 ET
Amarin reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Amarin reported for 2022 q1
SEC form 10
2022-03-01 00:00 ET
Amarin published news for 2021 q4
SEC form 8
2022-03-01 00:00 ET
Amarin published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Amarin published news for 2021 q4
SEC form 10
2021-11-03 00:00 ET
Amarin published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
Amarin published news for 2021 q3
SEC form 8
2021-08-05 00:00 ET
Amarin published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Amarin published news for 2021 q2
SEC form 10
2021-04-29 00:00 ET
Amarin published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
Amarin published news for 2021 q1